620989-08-4Relevant academic research and scientific papers
Discovery and structure-activity study of a novel benzoxaborole anti-inflammatory agent (AN2728) for the potential topical treatment of psoriasis and atopic dermatitis
Akama, Tsutomu,Baker, Stephen J.,Zhang, Yong-Kang,Hernandez, Vincent,Zhou, Huchen,Sanders, Virginia,Freund, Yvonne,Kimura, Richard,Maples, Kirk R.,Plattner, Jacob J.
scheme or table, p. 2129 - 2132 (2009/12/07)
A series of phenoxy benzoxaboroles were synthesized and screened for their inhibitory activity against PDE4 and cytokine release. 5-(4-Cyanophenoxy)-2,3-dihydro-1-hydroxy-2,1-benzoxaborole (AN2728) showed potent activity both in vitro and in vivo. This compound is now in clinical development for the topical treatment of psoriasis and being pursued for the topical treatment of atopic dermatitis.
3-Benzimidazol-2-yl-1H-indazoles as potent c-ABL inhibitors
McBride, Christopher M.,Renhowe, Paul A.,Gesner, Thomas G.,Jansen, Johanna M.,Lin, Julie,Ma, Sylvia,Zhou, Yasheen,Shafer, Cynthia M.
, p. 3789 - 3792 (2008/12/23)
The 3-benzimidazol-2-yl-1H-indazole scaffold was developed as an alternate scaffold for our receptor tyrosine kinase (RTK) inhibitor program. In exploring the SAR of this series, it was discovered that a subset of these compounds potently inhibit the enzy
N-substituted-heteroaryloxy-aryloxy-pyrimidine-2,4,6-trione metalloproteinase inhibitors
-
Page 31, (2010/02/06)
The present invention relates to N-substituted-heteroaryloxy-aryloxy-2,4,6-trione metalloproteinase inhibitors of the formula wherein X, A, Y, B, G, and R1 are as defined in the specification, and to pharmaceutical compositions and methods of treating inflammation, cancer and other disorders.
